Laurion Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Laurion Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,250	Closed	-$2.91M	–	697
2021 Q2	$2.91M	Buy	+6,250	New	+$3.41M	0.02%	333
2020 Q2	–	Sell	-1,875	Closed	-$671K	–	926
2020 Q1	$671K	Buy	+1,875	New	+$674K	0.01%	548
2018 Q3	–	Sell	-625	Closed	-$92K	–	1206
2018 Q2	$92K	Hold	625	–	–	﹤0.01%	1254
2018 Q1	$102K	Buy	+625	New	+$104K	﹤0.01%	1274

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Laurion Capital Management's BTAI Position: Q3 2021 in Review

Laurion Capital Management sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 6,250 shares — an estimated $2.91M sold.

Laurion Capital Management first reported a position in BTAI in Q1 2018 and held it in 4 quarters. The position peaked at $2.91M in Q2 2021. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

Laurion Capital Management reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
Laurion Capital Management sold 6,250 BioXcel Therapeutics shares in Q3 2021, an estimated $2.91M.
Laurion Capital Management first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 4 quarters.
Laurion Capital Management's BioXcel Therapeutics position peaked at $2.91M in Q2 2021.
103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.